home / stock / mdxg / mdxg news

MDXG News and Press, MiMedx Group Inc From 09/13/21

Stock Information
Company Name: MiMedx Group Inc
Stock Symbol: MDXG
Market: OTC
Website: mimedx.com
Menu
MDXG MDXG Quote MDXG Short MDXG News MDXG Articles MDXG Message Board
Get MDXG Alerts

News, Short Squeeze, Breakout and More Instantly...
MDXG - ATER, AXTI and OIIM among mid-day movers

Gainers: Itamar (NASDAQ:ITMR) +46%. Aterian (NASDAQ:ATER) +40%. aTyr Pharma (NASDAQ:LIFE) +37%. iRhythm Technology (NASDAQ:IRTC) +34%. BELLUS (NASDAQ:BLU) +26%. Leap Therapeutics  (NASDAQ:LPTX) +30%. REGENXBIO (NASDAQ:RGNX) +25%. Datasea (NASDAQ:DTSS) +20%. Uranium Royalty (NASDAQ:UROY) ...
MDXG - Why Shares of MiMedx Are Collapsing Today

Shares of MiMedx Group (NASDAQ: MDXG) are down more than 60% as of 12:15 p.m. EDT today after a pair of clinical trials failed to demonstrate their intended benefits. The biotech focuses on regenerative medicine using amniotic tissue as a platform. The results today were fro...

MDXG - Itamar Medical, aTyr Pharma leads healthcare gainers; MiMedx, Silverback Therapeutics among major losers

Gainers: Itamar Medical ITMR +45%, aTyr Pharma LIFE +35%, iRhythm Technologies (NASDAQ:IRTC) +33%, REGENXBIO RGNX +20%, Leap Therapeutics LPTX +15%. Losers: MiMedx MDXG -61%, Silverback Therapeutics (NASDAQ:SBTX) -24%, Dynavax T...

MDXG - MIMEDX Reports Top-line Data from Two Late-Stage Musculoskeletal Trials with Proprietary Amniotic Tissue Technology

Phase 2B Knee Osteoarthritis (KOA) Study Top-line Interim Results Demonstrate Varied Efficacy Signals between Patient Cohorts Company to Pursue Phase 3 KOA Confirmatory Studies Initial Review of Phase 3 Plantar Fasciitis Trial Data Does Not Support a Biologics License Ap...
MDXG - MIMEDX Announces Effectiveness of Shelf Registration Statement

MARIETTA, Ga., Sept. 08, 2021 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, today announced the shelf registration statement on Form S-3 ...

MDXG - MIMEDX to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

MARIETTA, Ga., Sept. 07, 2021 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, today announced that Timothy R. Wright, Chief Executive Offic...

MDXG - My 32 Stock Retirement Portfolio Breaks $400,000 In August

My portfolio, built specifically for my retirement ~20+ years from now, eclipses new highs as the market continues to grind higher. Making monthly contributions, even though they seem small at the time, makes all the difference in the world over time in helping create a valuable retir...
MDXG - MIMEDX Announces Filing of Shelf Registration Statement with Securities and Exchange Commission

S-3 Eligibility Enabled by Accomplishment of Multiple Financial Milestones MARIETTA, Ga., Aug. 27, 2021 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), an industry leader in utilizing amniotic tissue as a platform for ...

MDXG - Medicare Data: Significant Reductions in Amputations, Emergency Visits, and Hospital Readmissions Associated with Advanced Treatment Using Skin Substitute Products for Lower Extremity Diabetic Ulcers (LEDUs)

New study shows advanced treatment (AT) for management of LEDUs among Medicare beneficiaries is associated with significant reductions in major and minor amputation, emergency department (ED) use, and hospital readmissions vs. LEDUs managed without AT (NAT) MARIETTA, Ga., Aug. 17,...

MDXG - MIMEDX Promotes Marion Snyder to Chief of Staff, Senior Vice President, Government Affairs

Promotion Recognizes Skilled Leadership and Contributions to MIMEDX’s Continued Growth MARIETTA, Ga., Aug. 12, 2021 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), an industry leader in utilizing amniotic tissue as a ...
Previous 10 Next 10